Soligenix (NASDAQ:SNGX) CEO Christopher Schaber Purchases 15,132 Shares

Soligenix Inc. (NASDAQ:SNGX) CEO Christopher Schaber bought 15,132 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was purchased at an average cost of $1.32 per share, with a total value of $19,974.24. Following the purchase, the chief executive officer owned 15,511 shares of the company’s stock, valued at $20,474.52. This represents a 3,992.61% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Soligenix Price Performance

Shares of SNGX opened at $1.38 on Friday. The firm has a market cap of $5.92 million, a P/E ratio of -0.36 and a beta of 1.95. The stock has a 50 day simple moving average of $2.61 and a two-hundred day simple moving average of $2.09. Soligenix Inc. has a 1 year low of $1.09 and a 1 year high of $6.23.

Soligenix (NASDAQ:SNGX) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.03). On average, equities analysts anticipate that Soligenix Inc. will post -4.65 earnings per share for the current year.

Wall Street Analyst Weigh In

SNGX has been the subject of a number of recent analyst reports. Wall Street Zen downgraded Soligenix to a “strong sell” rating in a report on Saturday, August 16th. Alliance Global Partners cut their target price on Soligenix from $10.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, July 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a research note on Saturday, September 27th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Soligenix stock. Connective Capital Management LLC lifted its stake in Soligenix Inc. (NASDAQ:SNGX) by 17.6% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,481 shares of the biopharmaceutical company’s stock after buying an additional 17,848 shares during the quarter. Connective Capital Management LLC owned about 3.67% of Soligenix worth $157,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.